Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Infectious diseases

Approved COVID-19 antibody test 'not intended for home use', manufacturer warns

Abbott, the manufacturer of a COVID-19 test, has said it should not be used as a finger-prick test, as high street multiple Superdrug says it has sold out of its £69 antibody home kit.

Open access article

The Royal Pharmaceutical Society has made this article free to access in order to help healthcare professionals stay informed about an issue of national importance.

To learn more about coronavirus, please visit:

Abbot laboratories


Claims that Abbot’s ARCHITECT SARs-CoV-2 test can be used at home with finger-prick blood samples are “false and not correct”, the manufacturer has stated

A Public Health England-approved antibody test for SARS-CoV-2 that was being sold for use at home with a finger-prick blood test, is not intended to be used in this way, the manufacturer has said.

The test, manufactured by Abbott, and found to be a “highly specific assay” by Public Health England, was launched for sale to the public by high street multiple, Superdrug, on 20 May 2020. This made Superdrug “the first high street retailer to offer a COVID-19 [SARS-CoV-2] antibody blood test” via its online doctor service.

However, Abbott has said that it has no evidence that the test can be carried out using a finger-prick blood sample.

In a statement to The Pharmaceutical Journal on 21 May 2020, a spokesperson for Abbott said its ‘ARCHITECT’ SARS-CoV-2 test “was developed for use by laboratory professionals only” and “is unable to give any guarantees or make claims for the performance of our test if it is used with finger-stick blood”. 

The Superdrug website was changed later on 20 May 2020 to say that the test was no longer available “due to the high demand of orders”.

A spokesperson for Superdrug told The Pharmaceutical Journal at the time of the launch that its laboratory was “adhering to all requirements as set by Abbott that the ‘ARCHITECT’ SARS-CoV-2 IgG (6R86) test is conducted using a serum or plasma sample (no requirement of a venous sample)”.

However, Abbott’s statement said the test “has been validated for use with a venous blood sample that is taken by a healthcare provider”.

“The test is not intended for use as a home test and it should not be conducted with a finger stick blood sample,” as the manufacturer “does not have any data to support that finger-stick blood samples can be used with our test”.

“The use of the Abbott name, our data and our materials by any companies in connection with these home tests has not been authorised by Abbott, and we regard them as misleading in that these sites imply Abbott condones the use of finger stick samples with our test. This is false and not correct,” they continued.

“We took immediate action upon learning of this and have taken steps to have companies remove our name from their website and retract any misleading information relating to our test.”

Abbott would not confirm which companies it has asked to remove information from their websites.

Responding to the statement from Abbott, a spokesperson for Superdrug said that its “accredited laboratory partner, TDL … has provided evidence of validation of the use of a capillary blood sample”.

“As a [UK Accreditation Service]-accredited laboratory, TDL has a responsibility to carry out validation [testing]. They conducted an internal study using samples provided from patients that have previously tested positive, using a polymerase chain reaction swab test, to coronavirus (SARS-CoV-2),” the spokesperson added.

“The laboratory partner that we work closely with to supply this test has provided evidence of validation of the use of a capillary blood sample. The laboratory has provided this information regarding their specificity.”

A spokesperson for Boots told the The Pharmaceutical Journal it was looking at a “range of ways” to make a COVID-19 antibody testing service available for its customers.

They added that it is only planning to start selling antibody tests “once we’re completely confident that we can provide our customers with antibody testing, which uses equipment or technology that has been approved by the appropriate bodies and the right support and advice to interpret the results”.

However, Well Pharmacy has said it is also planning to sell the finger-prick test from its online shop for £69, regardless of the comments from Abbott.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2020.20207990

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now
  • Strategic Medicines Management

    Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.